Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc. is positioned positively within the biopharmaceutical sector due to its innovative focus on developing autologous tumor infiltrating lymphocyte (TIL) therapies, particularly the ITIL-306, which targets multiple solid tumors using its proprietary CoStAR platform. The validation of tumor-associated antigens in significant cancer types, such as ovarian and renal cancers, showcases the potential for broad market applications and underscores the company's competitive advantage in a growing field. Additionally, the anticipated positive updates related to the bispecific class in the industry may further enhance investor confidence in the efficacy and market traction of TIL therapies, providing a favorable outlook for Instil Bio's future performance.

Bears say

Instil Bio Inc. faces significant skepticism from bearish investors who are concerned about the minimal improvements in overall survival (OS) curves post-update, which may indicate a lack of efficacy in its trials. Additionally, the company is exposed to multiple risks, including potential delays in clinical advancement and the possibility of unfavorable clinical data, particularly regarding its candidates AXN-2510 for NSCLC and SCLC. The financial outlook is further clouded by the threat of medium- to long-term dilution, which could pressure the company's enterprise value perception, currently sitting at $136 million.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.